Palleon Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
E-602 / Palleon Pharma
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Completed
1/2
69
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
10/24
10/24
E-434 / Palleon Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
E-602 / Palleon Pharma
GLIMMER-01, NCT05259696: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein

Completed
1/2
69
US
E-602, Cemiplimab, Libtayo, REGN2810
Palleon Pharmaceuticals, Inc.
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
10/24
10/24
E-434 / Palleon Pharma
No trials found

Download Options